Tricida (Tricida) Cash And Cash Equivalents : $17.74 Mil (As of Sep. 2022)

View and export this data going back to 2018. Start your Free Trial

What is Tricida Cash And Cash Equivalents?

Tricida's quarterly cash and cash equivalents increased from Mar. 2022 ($17.71 Mil) to Jun. 2022 ($22.15 Mil) but then stayed the same from Jun. 2022 ($22.15 Mil) to Sep. 2022 ($17.74 Mil).

Tricida's annual cash and cash equivalents increased from Dec. 2019 ($18.57 Mil) to Dec. 2020 ($137.86 Mil) but then declined from Dec. 2020 ($137.86 Mil) to Dec. 2021 ($21.11 Mil).

Tricida Cash And Cash Equivalents Historical Data

The historical data trend for Tricida's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tricida Cash And Cash Equivalents Chart

Tricida Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash And Cash Equivalents

Get a 7-Day Free Trial

9.77

37.17

18.57

137.86

21.11

Tricida Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Cash And Cash Equivalents	Get a 7-Day Free Trial															16.99	21.11	17.71	22.15	17.74

Tricida Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Tricida (OTCPK:TCDAQ) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Tricida Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Tricida's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Tricida (Tricida) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tricida Inc (OTCPK:TCDAQ) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

7000 Shoreline Court, Suite 201, South San Francisco, CA, USA, 94080

Website

https://www.tricida.com

Tricida Inc is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. The primary area of focus is to slow the progression of chronic kidney disease through the treatment of metabolic acidosis.

Executives

David P Bonita	director, 10 percent owner	C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Robert J Alpern	director	YALE SCHOOL OF MEDICINE, 333 CEDAR STREET, C203 SHM, NEW HAVEN CT 06520
Venrock Healthcare Capital Partners Ii, L.p.	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Sibling Capital Fund Ii-b L.p.	10 percent owner, other: *possible member of 10% group	2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Sibling Capital Ventures Ii Llc	10 percent owner, other: *possible member of 10% group	2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Brian M. Isern	10 percent owner, other: *possible member of 10% group	2033 6TH AVE., SUITE 330, SEATTLE WA 98121
Sibling Capital Fund Ii-c L.p.	10 percent owner, other: *possible member of 10% group	2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Sibling Capital Ventures Iii Llc	10 percent owner, other: *possible member of 10% group	2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Sibling Capital Fund Ii-a L.p.	10 percent owner, other: possible member of 10% group	500 YALE AVE N, SEATTLE WA 98109
Vhcp Management Eg, Llc	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Healthcare Capital Partners Eg, L.p.	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Vhcp Co-investment Holdings Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036